This Powerpoint describes what is Flow chemistry, what are its advantages over batch method, Continuous flow reactor and Applications of Continuous flow chemistry.
Process chemistry AS PER PCI SYLLABUS FOR M.PHARMShikha Popali
pharmaceutical process chemistry is process WHERE FROM THE RESEARCH TO FINISH PRODUCT INCLUDING THE PRODUCT DEVELOPMENT AT LABORATORY LEVEL THAN PILOT PLANT WHERE THE PRODUCT IS MANUFACTURED IN 10X THAN FINAL AT 100X THAT IS SCALE UP PLANT.
This Powerpoint describes what is Flow chemistry, what are its advantages over batch method, Continuous flow reactor and Applications of Continuous flow chemistry.
Process chemistry AS PER PCI SYLLABUS FOR M.PHARMShikha Popali
pharmaceutical process chemistry is process WHERE FROM THE RESEARCH TO FINISH PRODUCT INCLUDING THE PRODUCT DEVELOPMENT AT LABORATORY LEVEL THAN PILOT PLANT WHERE THE PRODUCT IS MANUFACTURED IN 10X THAN FINAL AT 100X THAT IS SCALE UP PLANT.
Asymmetric synthesis (As per new syllabus of PCI)
Methods of asymmetric synthesis using chiral pool
Chiral auxiliaries and catalytic asymmetric synthesis
Enantiopure seperation
Stereoselective synthesis
Recent advances
References
MERITS OF MICROWAVE ASSISTED REACTIONS
DEMERITS OF MICROWAVE ASSISTED REACTIONS
MECHANISM OF MICROWAVE HEATING
EFFECTS OF SOLVENTS IN MICROWAVE ASSISTED SYNTHESIS
MICROWAVE VERSUS CONVENTIONAL SYNTHESIS
MICROWAVE INSTRUMENTATION
VARIOUS TYPES OF MICROWAVE ASSISTED ORGANIC REACTIONS
APPLICATIONS OF MICROWAVE ASSISTED REACTIONS
OXIDATION [PHARMACEUTICAL PROCESS CHEMISTRY]Shikha Popali
INTRODUCTION TO OXIDATION , WHICH IS PROCESS OF ADDITION OF OXYGEN TO THE COMPOUND IN RPOCESS CHEMISTRY AND LIQUID PHASE OXIDATION AND OTHER OXIDISING AGENTS ARE DISCUSSED.
PTC IS THE PHASE TRANSFER CATALYSIS HERE TYPES OF PTC ARE DISCUSSED , THEORIES OF CATALYSIS AND MECHANISM OF PTC, ADVANTAGES OF PTC, APPLICATION OF PTC
Contents includes at least three strategies of synthesis for each of three, four, five and six membered heterocylic ring with one or two heteroatoms. One mechanism described out of the three strategies. Few name reactions are described and the other are simple synthetic methods. This presentation was prepared for the partial fulfillment of Master of Pharmacy. The content was taken from the various books, mentioned in slide with the title of references.
APIT, OPTIMISATION ,SCALE UP ,WORK UP, GREEN CHEMISTRY ,MSSDS, SOLVENT SELECTION, EFFLUENT TREATMENT AND MINIMISATION ,HEALTH HAZARD AND SAFETY HAZARD, IN PROCESS CONTROL
Asymmetric synthesis (As per new syllabus of PCI)
Methods of asymmetric synthesis using chiral pool
Chiral auxiliaries and catalytic asymmetric synthesis
Enantiopure seperation
Stereoselective synthesis
Recent advances
References
MERITS OF MICROWAVE ASSISTED REACTIONS
DEMERITS OF MICROWAVE ASSISTED REACTIONS
MECHANISM OF MICROWAVE HEATING
EFFECTS OF SOLVENTS IN MICROWAVE ASSISTED SYNTHESIS
MICROWAVE VERSUS CONVENTIONAL SYNTHESIS
MICROWAVE INSTRUMENTATION
VARIOUS TYPES OF MICROWAVE ASSISTED ORGANIC REACTIONS
APPLICATIONS OF MICROWAVE ASSISTED REACTIONS
OXIDATION [PHARMACEUTICAL PROCESS CHEMISTRY]Shikha Popali
INTRODUCTION TO OXIDATION , WHICH IS PROCESS OF ADDITION OF OXYGEN TO THE COMPOUND IN RPOCESS CHEMISTRY AND LIQUID PHASE OXIDATION AND OTHER OXIDISING AGENTS ARE DISCUSSED.
PTC IS THE PHASE TRANSFER CATALYSIS HERE TYPES OF PTC ARE DISCUSSED , THEORIES OF CATALYSIS AND MECHANISM OF PTC, ADVANTAGES OF PTC, APPLICATION OF PTC
Contents includes at least three strategies of synthesis for each of three, four, five and six membered heterocylic ring with one or two heteroatoms. One mechanism described out of the three strategies. Few name reactions are described and the other are simple synthetic methods. This presentation was prepared for the partial fulfillment of Master of Pharmacy. The content was taken from the various books, mentioned in slide with the title of references.
APIT, OPTIMISATION ,SCALE UP ,WORK UP, GREEN CHEMISTRY ,MSSDS, SOLVENT SELECTION, EFFLUENT TREATMENT AND MINIMISATION ,HEALTH HAZARD AND SAFETY HAZARD, IN PROCESS CONTROL
Scale Up Methodology for the Fine Chemical Industry - The Influence of the Mi...Aldo Shusterman
Abstract- In this article the authors, based on the VisiMix Software, the experience of VisiMix users and personal knowledge from more than ten years of experience using VisiMix for API, Fine Chemicals and others, processes simulation, show a Method for Scale Down – Scale Up of Batch – Semi Batch operations built under Hydrodynamics study of the Mixing procedure in the reactor system. The use of the recommended method will offer the user the possibility to achieve the best results during production stage with saving among time and currency, and at the same time increasing the knowledge of the performed process. Several examples at the end of the article show the benefits of the proposed VisiMix Method Loops for Scale Down - Scale Up and Hydrodynamics Considerations.
Scale Up Methodology for the Fine Chemical Industry - The Influence of the Mi...Aldo Shusterman
Chemical production is a result of several chemical reactions and purification steps. Purification steps and processes yield are a direct function of the level of understanding of the reaction system. Reaction quality results have a tremendous impact in separation technology.
Chemical production is frequently performed on stirred vessels that are operated at batch or semi-batch configuration. The choice process configuration is determined at the development stage of the project. Therefore, if the chemical reaction and mixing are not well understood, wrong selections will be adopted in the process development
CRO Company for Mode of Action & Efficacy Test for Drugs | InvivoBiosystemsWenlan Hu
Compound testing takes shares of a huge part of the drug development and health-related compound market. In order to find a CRO that is both friendly for budget saving and efficient at the same time is not easy. IVB uses a three staged compound assessment which includes RNAseq, whole transcriptome analysis, and other techniques to help our clients better understand the mode of action and efficacy of a particular compound.
The compound characterization market is growing increasingly profitable and competitive at the same time. In order to develop a new compound product, the testing step is indispensable. Unlike drug discovery, compound testing is not as restrictive, but understanding the main workflow is still necessary to excel in the market. In order to help you improve both the efficiency and safety of compound testing, we developed the protocol to assist you in your findings.
Development and Scale Up Of a Chemical Process in Pharmaceutical Industry: A ...IJERA Editor
Every process has its own significance and one has to study factors which impact to the process and its
procedure to be followed. This paper is more concerned of how a process is scaled up from lab scale to pilot
plant scale, which is the major step in any industry because moving directly towards manufacturing level
consumes time and money. The report introduces about pharmaceutical industry and how it is different from
the other industries and provides firsthand experience for all the engineers to explore the equipment, process
and unit operations included in it. First aspect of scale up is safety and then comes economy, purity and
optimums. It includes the process and its unit operations such as reactors, distillation, filtration,
crystallization, drying and the equipment involving these operations. Consequently, the scale up rules,
factors influenced strategies and other considerations are observed. To learn and understand the unit process
and operations with their importance, a case study taking one of the stages of production is discussed here.
MUTUAL PRODRUG IS DISCUSSED HERE IN DETAIL WITH ITS MULTIPLE TYPES AND FUCTIONAL GROUPS IT IS USE FOR AND FAILURE WITH PRODRUGS, WITH PHARMACEUTICAL EXAMPLES AND STRUCTURE ARE ALSO SHARE, SYNTHETIC APLLICATIONS.
HERE PRESENTS AN OLIGONUCLEOTIDE THERAPY, ITS INTRODUCTION TO OLIGONUCLEOTIDE, ITS TECHNIQUES, DEVELOPED METHODS AND THEIR APP,LICATIONS IN PHARMACEUTICAL ARE HERE DISCUSSED IN DETAIL
Synthetic reagent and applications OF ALUMINIUM ISOPROPOXIDEShikha Popali
SYNTHETIC REAGENTS AND APPLICATIONS OF ALUMINIUM ISOPROPOXIDE ITS ALTERNATIVE NAMES AND ITS PHYSICAL PROPERTIRS , HANDLING, STORAGE, PRECAUTIONS, PREPARATIONS, SYNTHETIC APPLICATIONS
SWERTIA CHIRATA NATURAL PRODUCT OF PHARMACEUTICALSShikha Popali
HERE THE NATURAL PRODUCT SERTIA CHIRATA IS DISCUSSED WITH ITS COMMON NAME, CHEMICAL CONSTITUENTS, ACTIVE CONSTITUENTS, SAR, MEDICINAL ACTIVITY AND MORE
THE DCC I.E. DICYCLOCARBODIIMDE IS A REAGENT AND HERE THE DETAIL ACCOUNT ON IT IS GIVEN INCLUDING MOLECULAR WEIGHT, STRUCTURE, SYNTHESIS AND PHYSICAL PARAMETERS AND APPLICATIONS FOR OTERS SYNTHESIS ARE ALSO DISCUSSED, THE DIFFERENT SYNTHESIS WITH DCC COMBINATION ARE ALSO MENTIONED
COMPARATIVE EVALUATION OF DIFFERENT PARACETAMOL BRANDSShikha Popali
THE PARACETAMOL TABLETS IS COMMONLY TAKEN AND PRESCRIBED FOR FEVER , SO HERE WE HAVE MADE PRACTICAL IS IT TRUE EVALUATION LABEL AND WHICH BRAND IS MORE SAFE.
The Roman Empire A Historical Colossus.pdfkaushalkr1407
The Roman Empire, a vast and enduring power, stands as one of history's most remarkable civilizations, leaving an indelible imprint on the world. It emerged from the Roman Republic, transitioning into an imperial powerhouse under the leadership of Augustus Caesar in 27 BCE. This transformation marked the beginning of an era defined by unprecedented territorial expansion, architectural marvels, and profound cultural influence.
The empire's roots lie in the city of Rome, founded, according to legend, by Romulus in 753 BCE. Over centuries, Rome evolved from a small settlement to a formidable republic, characterized by a complex political system with elected officials and checks on power. However, internal strife, class conflicts, and military ambitions paved the way for the end of the Republic. Julius Caesar’s dictatorship and subsequent assassination in 44 BCE created a power vacuum, leading to a civil war. Octavian, later Augustus, emerged victorious, heralding the Roman Empire’s birth.
Under Augustus, the empire experienced the Pax Romana, a 200-year period of relative peace and stability. Augustus reformed the military, established efficient administrative systems, and initiated grand construction projects. The empire's borders expanded, encompassing territories from Britain to Egypt and from Spain to the Euphrates. Roman legions, renowned for their discipline and engineering prowess, secured and maintained these vast territories, building roads, fortifications, and cities that facilitated control and integration.
The Roman Empire’s society was hierarchical, with a rigid class system. At the top were the patricians, wealthy elites who held significant political power. Below them were the plebeians, free citizens with limited political influence, and the vast numbers of slaves who formed the backbone of the economy. The family unit was central, governed by the paterfamilias, the male head who held absolute authority.
Culturally, the Romans were eclectic, absorbing and adapting elements from the civilizations they encountered, particularly the Greeks. Roman art, literature, and philosophy reflected this synthesis, creating a rich cultural tapestry. Latin, the Roman language, became the lingua franca of the Western world, influencing numerous modern languages.
Roman architecture and engineering achievements were monumental. They perfected the arch, vault, and dome, constructing enduring structures like the Colosseum, Pantheon, and aqueducts. These engineering marvels not only showcased Roman ingenuity but also served practical purposes, from public entertainment to water supply.
How to Make a Field invisible in Odoo 17Celine George
It is possible to hide or invisible some fields in odoo. Commonly using “invisible” attribute in the field definition to invisible the fields. This slide will show how to make a field invisible in odoo 17.
Honest Reviews of Tim Han LMA Course Program.pptxtimhan337
Personal development courses are widely available today, with each one promising life-changing outcomes. Tim Han’s Life Mastery Achievers (LMA) Course has drawn a lot of interest. In addition to offering my frank assessment of Success Insider’s LMA Course, this piece examines the course’s effects via a variety of Tim Han LMA course reviews and Success Insider comments.
Acetabularia Information For Class 9 .docxvaibhavrinwa19
Acetabularia acetabulum is a single-celled green alga that in its vegetative state is morphologically differentiated into a basal rhizoid and an axially elongated stalk, which bears whorls of branching hairs. The single diploid nucleus resides in the rhizoid.
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
2024.06.01 Introducing a competency framework for languag learning materials ...Sandy Millin
http://sandymillin.wordpress.com/iateflwebinar2024
Published classroom materials form the basis of syllabuses, drive teacher professional development, and have a potentially huge influence on learners, teachers and education systems. All teachers also create their own materials, whether a few sentences on a blackboard, a highly-structured fully-realised online course, or anything in between. Despite this, the knowledge and skills needed to create effective language learning materials are rarely part of teacher training, and are mostly learnt by trial and error.
Knowledge and skills frameworks, generally called competency frameworks, for ELT teachers, trainers and managers have existed for a few years now. However, until I created one for my MA dissertation, there wasn’t one drawing together what we need to know and do to be able to effectively produce language learning materials.
This webinar will introduce you to my framework, highlighting the key competencies I identified from my research. It will also show how anybody involved in language teaching (any language, not just English!), teacher training, managing schools or developing language learning materials can benefit from using the framework.
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
Instructions for Submissions thorugh G- Classroom.pptxJheel Barad
This presentation provides a briefing on how to upload submissions and documents in Google Classroom. It was prepared as part of an orientation for new Sainik School in-service teacher trainees. As a training officer, my goal is to ensure that you are comfortable and proficient with this essential tool for managing assignments and fostering student engagement.
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
2. INTRODUCTION
2
“Drug” –a compound that interacts with a biological
molecule, triggering a physiological effect.
Drugs (active pharmaceutical ingredients) can be classified
into 4 groups depending on their origin;
1) Natural products
2) Fermentation products
3) Semi-synthetics –substances produced by partial
synthesis
4) Completely synthetic products
3. Background
Average cost of developing a drug was $500 million in 1999 and
takes 12-25 years usually.
The chances of a candidate drug that is identified becoming
approved is approximately 1 in 10,000. (For every 10,000 trial
compounds, 20 reach trials on animals, 10 reach clinical trials on
humans and 1 gets FDA approval)
Discovery stage (research labs) involves preparation of potential drug
compound on 10 mg to 10 g scale. Toxicology tests are carried out on
this material. If these are successful, greater quantities of the
compound will be required for clinical trials.
At this stage, development work begins.
-Immediate goal – to produce clinical trial material.
-Longer term goal– to develop a commercially viable scaled-up
validated process.
3
4. Terminology
Development–covers all work between research and
production (e.g. analytical, chemical, formulation) and
continues when production begins.
Scale-up– process of going from laboratory preparation to
whatever scale of manufacture is required to satisfy the
market demand (usually 1,000 to 50,000 L range)
Technology Transfer
-Transfer between manufacturing sites
-Transfer within a manufacturing site
(Partnerships for collaborative R & D)
4
5. Process chemistry
5
Process chemistry involves development of practical,
safe and cost effective processes for the synthesis of
compounds selected to progress from
research/discovery to a larger scale.
Within the pharmaceutical industry synthetic routes developed within
medicinal chemistry often have to be completely redesigned by process
chemists, and this is in part due to their differing requirements.
The differences between medicinal and process chemistry and the multitude
of factors that need to be taken into consideration when scaling up a
chemical process.
6. Medicinal
chemistry Vs
For medicinal chemists diversity
and flexibility of a route is
important.
They synthesise a wide range of
analogues of a lead compound
on a small scale (20 mg) for
testing in order to increase
activity, reduce side effects and
to produce an API that may be
easily and efficiently
administered to the patient.
For this the compound must
have the right properties in
terms of activity, toxicity,
solubility, pharmacokinetics and
pharmacodynamics.
6
In contrast, process chemistry
involves development of
practical, safe and cost effective
processes for the synthesis of
compounds on a larger scale
(kg to several tonnes) that have
been selected to progress from
medicinal chemistry.
They generally therefore work
on a single target molecule and
define the best route to that
target.
Process chemistry
7. Process chemistry
7
The key stages in process chemistry for the development of an active
pharmaceutical ingredient
8. Process chemistry
8
The key stages in process chemistry for the development of an active
pharmaceutical ingredient
9. Process chemistry
9
The key stages in process chemistry for the development of an active
pharmaceutical ingredient
10. DOE in Process Parameters
10
With the most recent ICH and
FDA guidances endorsing a new
paradigm of process validation
based more on process
understanding and control of
parameters and less on product
testing.
After using process knowledgeto relate the attributes to each
process unit operation, the inputs and outputs of each unit
operation are defined to determine process parameters and in-
process controls.
11. DOE in Process Parameters
11
ICH Q8(R2)provides thefollowingdefinitionsusing thetermcritical:
• Critical process parameter (CPP).A processparameterwhosevariabilityhasanimpactona criticalquality
attributeand,therefore,shouldbemonitoredorcontrolledtoensurethe processproducesthe desired quality.
• Critical qualityattribute (CQA).A physical,chemical, biological,or microbiological propertyor
characteristicthatshouldbewithin anappropriatelimit, range,or distributiontoensurethedesired product
quality.
The definition for CPP states that a parameter is considered critical when its
variability has an impact on a CQA.
The amount of impact is not defined, which leads to the question, does even
a small impact to a CQA mean that the parameter is critical?
12. DOE in Process Parameters
12
It is not difficult to imagine the example of an extreme shift of a
process parameter having a minor impact on a CQA, whether
measurable or not.
Extreme temperatures can destroy many pharmaceutical
products; however, if a process inherently cannot produce such
temperatures, is temperature still considered to be critical and,
therefore, required to be monitored and controlled?
13. DOE in Process Parameters
13
When these definitions are strictly interpreted, then one of two
extremes would be:
• Every quality attribute is critical (they all ensure product
quality); every parameter is critical (product cannot be made
without controlling them)
• No parameter is critical because if they are controlled, all
quality attributes will pass specifications.
Reality lies somewhere between these extremes.
Logic and common sense dictate that additional criteria must be
necessary to aid in determining criticality.
There is great value in understanding not only if a
parameter/attribute is critical (i.e., has an impact), but also how
much impact the parameter/attribute has.
14. Process chemistry
14
The key stages in process chemistry for the development of an active
pharmaceutical ingredient
15. Process chemistry
15
The key stages in process chemistry for the development of an active
pharmaceutical ingredient
16. Process chemistry
16
The key stages in process chemistry for the development of an active
pharmaceutical ingredient
17. Term synthesis means in Greek
“put together”.
Synthetic chemistry is the “art” of building-up
complex molecular structures of compounds
putting together smaller, easily accessible
compounds.
17Synthetic Strategy
18. Synthetic Strategy 18
The construction of a complex organic structure, defined
target molecule, requires first of all the identification of the
smaller fragments that can be used to build-up the final target.
In the case of oligomers such as peptides,
oligosaccharides or oligonucleotides, the choice is
obvious: the constituent monomers are the building
blocks, and the synthesis requires the junction of those
monomers by condensation.
Two functional groups, one for each monomer, are involved
in the reaction
19. What is Development?
Broad range- between research and production- and
overlaps with both
In API (Active Pharmaceutical Ingredient) manufacture,
begins when active substance is identified and activity
demonstrated and more active substance is required.
Once a process that works on plant scale is produced and
is validated, development work still continues to improve
cost, efficiency, quality and environmental impact and to
deal with changing circumstances (vendors, equipment,
new regulations
(FDA21 CFR part11, Risk-Based Approach etc))
19
20. Development Stages
1) Chemical Development
Begins when activity of potential API is demonstrated
and more active substance is required (for clinical trials).
Process research;
–New synthetic routes (literature survey)
–Some initial optimisation
–Yield improvements
–Possibly scale-up to large lab equipment/ kilo lab (up to
about 20 L)
20
21. Development Stages cont’d
2) Process Development
-Optimization (change conditions and parameters)
-Minor change of route / intermediate
-Cheaper / more efficient reagents (new to market)
-Environmentally-friendly reagents and effluent
considerations
-Yield / concentration improvement
-Statistical methods
(e.g. Experimental Design; want maximum amount of unbiased
information about factors affecting a process from as few
observations as possible. Caution -“Facts are stubborn things.
Statistics are more pliable”)
21
22. Development Stages cont’d
Process Development cont’d
-SCALE-UP (Kilo Lab, Pilot plant trials)
-Transfer to Manufacturing
Parallel synthesis reactor block
-for optimization of condition
22
23. Development Stages cont’d
3) Process Support
Further optimisation (continuous improvement)
Fine-tuning of yield and throughput
Cost reduction
Troubleshooting (reworks, reprocessing,
deviations)
New vendor approval (use tests)
Waste minimisation (recycling)
23
24. Chemical Development
Selection of Synthetic Route
GET THE BEST ROUTE FROM THE BEGINNING -Difficult to
change later
Route should be short, efficient, robust and give a high yield
prior to scale-up
Discovery route often not the best. Expedient not optimal. (raw
materials may not be available in bulk, process may not be
efficient and may be safety hazards on large scale)
Compare like with like during selection (Same level of
optimisation and same scale. Are products of same purity
obtained? What is the cost comparison?)
Main constraint is TIME
24
25. Chemical Development
Selection of Synthetic Route cont’d
Shortest route usually best (less effluent, shorter lead
time, short plant occupation, less analytical work)
A convergent synthesis will be cheaper than a
divergent (linear) one with the same number of steps
Literature not always correct and perseverance with a
reaction is required
Better to try routes with high chance of success but
those which offer significant benefits should be
attempted even if little precedent
25
26. Chemical Development
In Convergent Synthesis, sections of the target molecule are prepared and
joined together to form the target molecule. A better yield than a linear
synthesis with the same number of steps will be obtained. The advantage is
significant if the subroutes converge close to the end of the synthesis.
(page 489, “Medicinal Chemistry, An Introduction”, G. Thomas).
26
27. Process Development
Optimisation of Synthetic Route –Once Selected
Work up very important
Can steps easily be combined (telescoping)?
Need excellent process control and understanding
of process limits (“stress” the reaction –higher
temperature, longer reaction time, less efficient
mixing). “Critical” steps / parameters (Quality)
Good analytical methods (standards)
Isolate and characterise by-products
A very innocuous process change can often have a
significant influence
27
28. Costing of Processes
Must be a standard costing procedure
Should be dated and updated
Assumptions should be stated
May be several factors leading to variation –scale,
plant configuration etc.
Compare like with like and be conservative
Carried out by independent person
Want to be able to see which factors increase cost
significantly and why
28
29. Scale up process
Pharmaceutical Process Scale-Up deals with a
subject both fascinating and vitally important for
the pharmaceutical industry—the procedures of
transferring the results of R&D obtained on
laboratory scale to the pilot plant and finally to
production scale.
29
30. Why Scale-up?
Scale up is basically needed for:
Market growth
Introduction of new processes
Reduction in making expensive errors in design
and operation
Concentrate on addressing areas of doubts and
uncertainty
Economic feasibility
30
31. Scale-up
Product and process development for scaling up is typically move in small
steps.
For instance, the development is initially from lab scale to
bench scale then move to pilot scale and finally to
commercialization scale.
By performing scale up step by step, the risk with large
investments could be lessen.
31
Several
Steps
32. Application of the SELECT
criteria to scale up
Safety
Environmental
Legal
Economic
Control
Throughput
32
33. Application of the SELECT
criteria
Safety
Safety is the number one criteria for research
and development. It describes safety risks
including thermal and reactive hazards, and
toxicity, which become increasingly important
as processes are scaled up.
33
34. Application of the SELECT
criteriaEnvironmental
The pharmaceutical industry follows the
environmental ideals of preventing, minimising and
rendering harmless any reagents used and wastes
generated from processes.
Different metrics are utilised within the industry to
track and minimise environmental impact.
Steps taken to improve environmental credentials for
a process are considered
34
35. Application of the SELECT
criteriaLegal
It describes legal considerations including
regulation of substances by governments,
environmental legislation and patent law.
35
36. Application of the SELECT
criteria
Economic
It discusses economic considerations.
36
37. Application of the SELECT
criteriaControl
Quality control is essential for commercial production
of an API (active pharmaceutical ingredient).
Selectivity, stability, purification, registration and
validation of processes, product specifications and
genotoxic impurities all need to be considered to
ensure quality is suitable for market.
37
38. Application of the SELECT
criteriaThroughput
Making sure that we can produce enough within a given time, where
chemical yields plays an important role, trying to work as concentrated as
possible; if you have one very diluted step in the middle of synthesis this
can really be a bottleneck.
If you have to perform that several steps before the API this might be real
bottleneck and not allow you to make a sufficient volume.
What's quite often used is a telescoping of reactions, meaning you work in
the same solvent for a number of consecutive steps which is really
improving throughput because
-you don't need to isolate intermediates,
-don't need to filter or centrifugate them,
-you don't need to dry them as
-you don't need to bring them again or dissolve them again for the next
step
So, that's one way to really improve throughput..
38
39. Summary: Application of the SELECT criteria
39
Criteria Sub-criteria Examples of Potential Issues
Safety
Process safety Explosions
Exposure to harmful substances Carcinogens, sensitisers
Environmental
Wasted resources Quantity & variety of solvents
Substances harmful to the
environment
Aquatic toxins, ozone depleters
Legal
Infringement of Intellectual Property
Competitor patenting key
intermediate
Regulation of reagents and
intermediates
Economic
Meeting Cost of Good (profit
margin)
Long synthesis or expensive starting
materials
Investment costs (equipment)
Control
Control of quality Meeting specifications/ GMP
Control of physical/chemical
parameters
Throughput
Time scale of manufacture Long synthetic route
Availability of starting materials Rare natural products
42. Planning for Scale up
Decide on process
Decide on batch size (not too large an increase)
Order raw materials (allow for 10% lower yield)
Carry out safety tests (Exotherms, HAZOP –hazard and
operability studies)
Discuss the process and plant requirements with
production manager/engineer (materials of
construction). Existing multipurpose plant usually.
Prepare safety data sheets and discuss handling of
hazardous reagents or intermediates
Ensure analytical procedures, equipment and staff are
available
42
43. Planning for Scale up cont’d
Write out detailed procedure (assume nothing);
Cleaning check and preparative work
Charging and weighing
Temperature and time limits
Sampling (in-process checks)
Transfers
Work-up and isolation
Drying and effluent disposal/treatment
Make allowance for delays / problems (rework procedures,
identify suitable “hold points”)
43
44. Planning for Scale up cont’d
Leave space in procedure to record data and
observations
Highlight safety procedures and steps to take if
spillage occurs
Provide training
44
45. Planning for Scale up cont’d
Significant Differences Between Lab and Plant
Heat transfer
Agitation (frothing)
Mass transfer (affects kinetics)
Visibility –of reactions, separations, for cleanliness checks
Separation (stirring, not shaking)
Time (slower additon rates and heating/cooling times,
longer work up)
Hazards (Toxic, Exotherm and Electrostatic)
Off-gas treatment
Safe and efficient sampling techniques needed (Process
Analytical Technology -Real time reaction monitoring; FT-IR,
Particle size, etc.)
45
46. Planning for Scale up cont’d
Process Development Taking Account of Differences Between Lab and
Plant Equipment
Use safety data already produced to help characterise
reaction
Study effect of scale-dependent factors (mixing, mass
transfer and heat transfer) at lab scale
Plan a logical set of experiments in time-frame available
Mimic plant conditions; slower addition of reagents, slower
rate of heat increase and decrease and mixing, lab system
should be baffled if reactors are (no vortex)
Obtain mass and heat transfer data for reactor type, agitator
type and solvents to be used.
Use simulation software to predict effects of mass and heat
transfer and mixing changes on scale-up.
46
48. Production Capacity
Table below shows the general production capacity of each scaling
up step in the process industries.
48
Scaling factor Typical production
capacity
Bench/ Laboratory 0.001 – 0.1 kg/h
Pilot Plant 10 – 100 kg/h
Demonstration Plant 100 – 1000 kg/h
Commercial Plant > 1000 kg/h
50. The collection and evaluation of data, from the
process design stage through commercial
production, which establishes scientific evidence that
a process is capable of consistently delivering quality products.
(FDA)
Documented evidence which provides a high degree of
assurance that a specific process will
consistently result in a product that meets
predetermined specifications and quality
characteristics. (WHO)
The documented evidence that the process,
operated within established parameters, can
perform effectively and reproducibly to produce a
medicinal product meeting its predetermined
specifications and quality attributes.
50
Validation of Large scale Process
51. Validation of Large scale Process
Traditional vs new paradigm
Post approval
changes/chan
ge
controls/risk
analysis
Development-
Basic
Process
validation-
3 batches
Pilot batch
manufacturing
Enhanced-
Development
and
process
qualification
Control
Strategy
ICH
Q8,
QbD
Continuous and
extensive
monitoring of
CQAs and
CPPs for each
production
batch
ICH Q9
and Q10
51
53. FDA, January 2011 WHO, Revised Annex 7 of
WHO GMP guide (draft for
comment)
European Medicines Agency
(EMA), February 2014
Continuous process
verification (CPV)
Continuous process verification
(CPV)
Alternative approaches:
-Traditional approach
-Continuous process
verification
-Hybrid approach
Process design and Initial
validation (process
qualification- PPQ) are initial
phases of CPV
Process design and initial
validation (initial process
verification) are initial phases of
CPV
CPV protocol to be supported
by extensive dev. information
and lab or pilot scale data.
Executed on each production
batch
No mention of number of
batches for initial process
performance qualification /
validation (rather must be
justified based on overall
product and process
understanding)
Mentions data on at least three
pilot or production batches
collected as part of process
design
Number of batches specified
for traditional approach
- minimum of three production
batches unless other wise
justified
53
Latest guidelines
54. Prospective validation Concurrent validation Retrospective validation
Protocol reviewed and
accepted, Product PQD; OR
Protocol executed before
submission or PQ
Protocol reviewed and
accepted, Product PQD
Protocol does not need to be
submitted
Execute and finalize process
validation on the first three
production batches
Execute and finalize process
validation on the first three
production batches
Prepare product quality
review report on already
manufactured production
batches
Commercial batches to be
released only after
satisfactorily conclusion of
process validation on three
batches
Each validation batch can be
validated and released.
Applicable for low demand
products (such as NTDs,
orphan drugs or other
seasonal products)
Applicable for submissions
meeting criteria for
established products as
described in Annex 4, TRS
970
54
Types of process validation and
dossier requirements
55. Design Qualification( DQ)
verification process to meet
particular requirement relating to
the quality of Pharmaceutical and
manufacturing process.
55
Process validation- Role of assessment
Design
qualificat
ion
Operatio
nal
qualificati
on
Performa
nce
qualificati
on
Process
validatio
n
GMP
Dossier
Performance qualification (PQ) (process
qualification)- process of testing to ensure that the
individual and combined systems function to meet
agreed performance criteria on a consistent basis
and to check how the result of testing is recorded.
The purpose is to ensure that the criteria specified
can be achieved on a reliable basis over a period of
time.
Operational Qualification (OQ) process of
testing to ensure individual and combined
systems function to meet agreed performance
criteria and to check how the result of testing
is recorded. The purpose is to ensure that all
the dynamic attributes comply with the
original design.
DQ plan covers user requirement,
user specification, Technical
specification and DQ report.
Process Validation :- Owners are responsible for Validating Their Processes (personnel,
equipment, methods, SOPs) to ensure compliance to cGMP/GLP regulations.
56. Case study; Process Development for
Labetalol Production
BACKGROUND
Labetalol –antihypertensive, 30,000 Kg p.a. produced by
Schering-Plough.
Labetalol Manufacturing Process
Mono-pot reaction in jacketed, glass-lined 10,000 L reactor.
Addition of liquid reagents and jacket temperature computer
controlled. Solid reagents charged manually via handwhole.
Phase separation using sight-glass.
Solid product from second step isolated by centrifugation.
Product tested to determine if recrystallisation necessary.
When required purity achieved, product is dried
56
57. Labetalol Process –Step 1
Solvent system modified to isopropanol / ethyl acetate containing hydrogen
bromide from methanol / ethyl acetate to reduce formation of third impurity.
Original process used chloroform.
Concentration was increased threefold increasing throughput and reducing
solvent waste.
57
Main Impurities
58. Labetalol Process – Step 2
Process Development
Large excess of dibenzylamine used to ensure reaction driven to completion (cheap reagent and easily
washed out)
Propylene oxide added as it reacts with HBr side-product as it’s produced. Presence of HBr would neutralise
dibenzylamine and no reaction to give product would occur. Propylene bromohydrin side-product easily
washed out.
Use gentle reflux to ensure propylene oxide doesn’t escape
58
+
59. Summary
Stages of development are Chemical Development, Process Development and Process
Support
Development essential before scale-up and validation –get process right
first
Time constraints a major factor
Have process in control (“critical” parameters)
Consider differences between lab and plant scale. Try to mimic plant
conditions in lab to anticipate effects when scale up.
Prepare process description carefully for scale-up
Development always on-going
59
Editor's Notes
Will cover syntheticaspects of pharmaceutical production processes.
Average cost of developing a drug was $500 million in 1999 and takes 12-25 years usually.
The chances of a candidate drug that is identified becoming approved is approximately 1 in 10,000. (For every 10,000 trial compounds, 20 reach trials on animals, 10 reach clinical trials on humans and 1 gets FDA approval)
Discovery stage (researchlabs) involves preparation of potential drug compound on 10 mg to 10 g scale. Toxicology tests are carried out on this material. If these are successful, greater quantities of the compound will be required for clinical trials.
At this stage, development work begins.
-Immediate goal–to produce clinical trial material.
-Longer term goal–to develop a commercially viable scaled-up validated process.
Synthetic Strategy
The construction of a complex organic structure, defined target molecule, requires first of all the identification of the smaller fragments that can be used to build-up the final target. In the case of oligomers such as peptides, oligosaccharides or oligonucleotides, the choice is obvious: the constituent monomers are the building blocks, and the synthesis requires the junction of those monomers by condensation. Two functional groups, one for each monomer, are involved in the reaction
Pharmaceutical Process Scale-Up deals with a subject both fascinating and vitally important for the pharmaceutical industry—the procedures of transferring the results of R&D obtained on laboratory scale to the pilot plant and finally to roduction scale. The primary objective of the text is to provide insight into the
practical aspects of process scale-up.
In mixing applications, scale-up is indeed concerned with increasing the linear dimensions from the laboratory to the plant size. On the other hand, processes
exist (e.g., tableting) for which “scale-up” simply means enlarging the output by increasing the speed. To complete the picture, one should point out
special procedures (especially in biotechnology) in which an increase of the scale is counterproductive and “scale-down” is required to improve the quality
of the product.
Scale is answer the question How to scale up from small scale to large scale?
Product and process development for scaling up is typically move in small steps.
• For instance, the development is initially from lab scale to bench scale then move to pilot scale and finally to commercialization scale.
• By performing scale up step by step, the risk with large investments could be lessen.
So the first criterion is Safety. No coincidence that this is really the number one criteria because we cannot afford to develop a process which on large scales is failing and that there is, for example, an explosion, where potentially people can die and that also there can be a complete destruction of the commercial supply chain, where also it could mean that patients do no longer have access to the medicine at a certain moment. There are at least two types of, or two categories of hazards. The first one is thermal and reactive hazards, has to do with the property of the reaction itself, to avoid that there is a thermal runaway we have the reaction mixture is getting to a temperature above which it is no longer stable. Second, on the large scale if there is a reaction where gas is evolving. It's completely different than on lab scale. If you are doing, for example, a BOC de-protection on small-scale, you do not worry about the fact that you are generating iso-butene, but on large scale we are talking about potentially significant volumes of iso-butene during the BOC de-protection. That's just one example, but at de-methylation with HBr where you are generating methyl bromide, you might not consider that in a lab environment but on large scale it's an important attention point. Certainly potential explosives, to be careful when handling these on large scale. Some of the reagents we are using are really corrosive, so on the long term we have to make sure that we can run, we can keep our equipment in a decent state. So we have to select the right equipment and protect it as much as possible. And also pyrophoric material, pyrophoric reagents, need special attention; for example, for storage, but also for dosing, for neutralization after the reaction . The second category are the toxic hazards, where the general principle is that first of all we try to avoid them. Avoid them by not using them, by using other reagents which are less toxic. If there is no real alternative, we try to reduce them; reduce the amount and after that we try to control that. On the one hand by containment and by engineering the process and the equipment, such that it's in a closed environment. And it's really needing also to protect the workers who has to handle these reagents on a large scale. And there's a difference between acute and chronic toxicity as you are aware of, for some of them you will observe it immediately that there's something wrong, for others you only see the effect after a long time. General principle is: If you can't scale it safely, don't scale it at all. A little bit of foam in the lab can be funny, not a problem, but some foaming on large scale, uncontrolled, and it can be, potentially, very toxic what's coming out of the reactor here. I'm sure you agree with me that you don't want to to see that..
So the first criterion is Safety. No coincidence that this is really the number one criteria because we cannot afford to develop a process which on large scales is failing and that there is, for example, an explosion, where potentially people can die and that also there can be a complete destruction of the commercial supply chain, where also it could mean that patients do no longer have access to the medicine at a certain moment. There are at least two types of, or two categories of hazards. The first one is thermal and reactive hazards, has to do with the property of the reaction itself, to avoid that there is a thermal runaway we have the reaction mixture is getting to a temperature above which it is no longer stable. Second, on the large scale if there is a reaction where gas is evolving. It's completely different than on lab scale. If you are doing, for example, a BOC de-protection on small-scale, you do not worry about the fact that you are generating iso-butene, but on large scale we are talking about potentially significant volumes of iso-butene during the BOC de-protection. That's just one example, but at de-methylation with HBr where you are generating methyl bromide, you might not consider that in a lab environment but on large scale it's an important attention point. Certainly potential explosives, to be careful when handling these on large scale. Some of the reagents we are using are really corrosive, so on the long term we have to make sure that we can run, we can keep our equipment in a decent state. So we have to select the right equipment and protect it as much as possible. And also pyrophoric material, pyrophoric reagents, need special attention; for example, for storage, but also for dosing, for neutralization after the reaction . The second category are the toxic hazards, where the general principle is that first of all we try to avoid them. Avoid them by not using them, by using other reagents which are less toxic. If there is no real alternative, we try to reduce them; reduce the amount and after that we try to control that. On the one hand by containment and by engineering the process and the equipment, such that it's in a closed environment. And it's really needing also to protect the workers who has to handle these reagents on a large scale. And there's a difference between acute and chronic toxicity as you are aware of, for some of them you will observe it immediately that there's something wrong, for others you only see the effect after a long time. General principle is: If you can't scale it safely, don't scale it at all. A little bit of foam in the lab can be funny, not a problem, but some foaming on large scale, uncontrolled, and it can be, potentially, very toxic what's coming out of the reactor here. I'm sure you agree with me that you don't want to to see that..
So the first criterion is Safety. No coincidence that this is really the number one criteria because we cannot afford to develop a process which on large scales is failing and that there is, for example, an explosion, where potentially people can die and that also there can be a complete destruction of the commercial supply chain, where also it could mean that patients do no longer have access to the medicine at a certain moment. There are at least two types of, or two categories of hazards. The first one is thermal and reactive hazards, has to do with the property of the reaction itself, to avoid that there is a thermal runaway we have the reaction mixture is getting to a temperature above which it is no longer stable. Second, on the large scale if there is a reaction where gas is evolving. It's completely different than on lab scale. If you are doing, for example, a BOC de-protection on small-scale, you do not worry about the fact that you are generating iso-butene, but on large scale we are talking about potentially significant volumes of iso-butene during the BOC de-protection. That's just one example, but at de-methylation with HBr where you are generating methyl bromide, you might not consider that in a lab environment but on large scale it's an important attention point. Certainly potential explosives, to be careful when handling these on large scale. Some of the reagents we are using are really corrosive, so on the long term we have to make sure that we can run, we can keep our equipment in a decent state. So we have to select the right equipment and protect it as much as possible. And also pyrophoric material, pyrophoric reagents, need special attention; for example, for storage, but also for dosing, for neutralization after the reaction . The second category are the toxic hazards, where the general principle is that first of all we try to avoid them. Avoid them by not using them, by using other reagents which are less toxic. If there is no real alternative, we try to reduce them; reduce the amount and after that we try to control that. On the one hand by containment and by engineering the process and the equipment, such that it's in a closed environment. And it's really needing also to protect the workers who has to handle these reagents on a large scale. And there's a difference between acute and chronic toxicity as you are aware of, for some of them you will observe it immediately that there's something wrong, for others you only see the effect after a long time. General principle is: If you can't scale it safely, don't scale it at all. A little bit of foam in the lab can be funny, not a problem, but some foaming on large scale, uncontrolled, and it can be, potentially, very toxic what's coming out of the reactor here. I'm sure you agree with me that you don't want to to see that..
So the first criterion is Safety. No coincidence that this is really the number one criteria because we cannot afford to develop a process which on large scales is failing and that there is, for example, an explosion, where potentially people can die and that also there can be a complete destruction of the commercial supply chain, where also it could mean that patients do no longer have access to the medicine at a certain moment. There are at least two types of, or two categories of hazards. The first one is thermal and reactive hazards, has to do with the property of the reaction itself, to avoid that there is a thermal runaway we have the reaction mixture is getting to a temperature above which it is no longer stable. Second, on the large scale if there is a reaction where gas is evolving. It's completely different than on lab scale. If you are doing, for example, a BOC de-protection on small-scale, you do not worry about the fact that you are generating iso-butene, but on large scale we are talking about potentially significant volumes of iso-butene during the BOC de-protection. That's just one example, but at de-methylation with HBr where you are generating methyl bromide, you might not consider that in a lab environment but on large scale it's an important attention point. Certainly potential explosives, to be careful when handling these on large scale. Some of the reagents we are using are really corrosive, so on the long term we have to make sure that we can run, we can keep our equipment in a decent state. So we have to select the right equipment and protect it as much as possible. And also pyrophoric material, pyrophoric reagents, need special attention; for example, for storage, but also for dosing, for neutralization after the reaction . The second category are the toxic hazards, where the general principle is that first of all we try to avoid them. Avoid them by not using them, by using other reagents which are less toxic. If there is no real alternative, we try to reduce them; reduce the amount and after that we try to control that. On the one hand by containment and by engineering the process and the equipment, such that it's in a closed environment. And it's really needing also to protect the workers who has to handle these reagents on a large scale. And there's a difference between acute and chronic toxicity as you are aware of, for some of them you will observe it immediately that there's something wrong, for others you only see the effect after a long time. General principle is: If you can't scale it safely, don't scale it at all. A little bit of foam in the lab can be funny, not a problem, but some foaming on large scale, uncontrolled, and it can be, potentially, very toxic what's coming out of the reactor here. I'm sure you agree with me that you don't want to to see that..
So the first criterion is Safety. No coincidence that this is really the number one criteria because we cannot afford to develop a process which on large scales is failing and that there is, for example, an explosion, where potentially people can die and that also there can be a complete destruction of the commercial supply chain, where also it could mean that patients do no longer have access to the medicine at a certain moment. There are at least two types of, or two categories of hazards. The first one is thermal and reactive hazards, has to do with the property of the reaction itself, to avoid that there is a thermal runaway we have the reaction mixture is getting to a temperature above which it is no longer stable. Second, on the large scale if there is a reaction where gas is evolving. It's completely different than on lab scale. If you are doing, for example, a BOC de-protection on small-scale, you do not worry about the fact that you are generating iso-butene, but on large scale we are talking about potentially significant volumes of iso-butene during the BOC de-protection. That's just one example, but at de-methylation with HBr where you are generating methyl bromide, you might not consider that in a lab environment but on large scale it's an important attention point. Certainly potential explosives, to be careful when handling these on large scale. Some of the reagents we are using are really corrosive, so on the long term we have to make sure that we can run, we can keep our equipment in a decent state. So we have to select the right equipment and protect it as much as possible. And also pyrophoric material, pyrophoric reagents, need special attention; for example, for storage, but also for dosing, for neutralization after the reaction . The second category are the toxic hazards, where the general principle is that first of all we try to avoid them. Avoid them by not using them, by using other reagents which are less toxic. If there is no real alternative, we try to reduce them; reduce the amount and after that we try to control that. On the one hand by containment and by engineering the process and the equipment, such that it's in a closed environment. And it's really needing also to protect the workers who has to handle these reagents on a large scale. And there's a difference between acute and chronic toxicity as you are aware of, for some of them you will observe it immediately that there's something wrong, for others you only see the effect after a long time. General principle is: If you can't scale it safely, don't scale it at all. A little bit of foam in the lab can be funny, not a problem, but some foaming on large scale, uncontrolled, and it can be, potentially, very toxic what's coming out of the reactor here. I'm sure you agree with me that you don't want to to see that..
Finally, the last criteria which is important is the Throughput. Making sure that we can produce enough within a given time, where chemical yields plays an important role, trying to work as concentrated as possible; if you have one very diluted step in the middle of synthesis this can really be a bottleneck. So, for example, certain types of chemistry like metathesis, ring-closing metathesis, which is in most cases run at very diluted conditions. If you have to perform that several steps before the API this might be real bottleneck and not allow you to make a sufficient volume. What's quite often used is a telescoping of reactions, meaning you work in the same solvent for a number of consecutive steps which is really improving throughput because you don't need to isolate intermediates, don't need to filter or centrifugate them, you don't need to dry them as you don't need to bring them again or dissolve them again for the next step so that's one way to really improve throughput..
Finally, the last criteria which is important is the Throughput. Making sure that we can produce enough within a given time, where chemical yields plays an important role, trying to work as concentrated as possible; if you have one very diluted step in the middle of synthesis this can really be a bottleneck. So, for example, certain types of chemistry like metathesis, ring-closing metathesis, which is in most cases run at very diluted conditions. If you have to perform that several steps before the API this might be real bottleneck and not allow you to make a sufficient volume. What's quite often used is a telescoping of reactions, meaning you work in the same solvent for a number of consecutive steps which is really improving throughput because you don't need to isolate intermediates, don't need to filter or centrifugate them, you don't need to dry them as you don't need to bring them again or dissolve them again for the next step so that's one way to really improve throughput..
Bench scale and lab scale systems are important early-stage tools for assessing and scaling new technology.
Application are a precursor to larger pilot and demonstration scale plants.
Researchers can then plot reaction yield and selectivity under a variety of operating conditions( Temp. Pressure Change solvent and volume.) Reactor volumes in bench and lab scale systems are typically less than 1000ml.
The most common operating configurations at the bench or lab scale are batch for continuous stirred tank reactor (CSTR), or autoclave etc.
Pilot plants Scale provide the first window into continuous processing and often incorporate unreacted feed or product recycle. They are the workhorse of the process development world. Catalyst performance tests are carried out to determine, or confirm, yield and selectivity data, and the lifetime of the catalyst is measured under a variety of operating conditions. Reactor size at the pilot plant scale typically ranges from 1 and 100 litres.
Demonstration Scale differ from pilot plants in that the equipment and process flowsheet much more closely resemble commercial scale operations.
Extended operating runs permit catalyst lifetime studies over a longer period of time, while significant quantities of final product can be generated for market testing.
Developers need to go to through the demonstration scale to prove to the market and investors that their technology meets its performance expectations, such as product yield and properties, and catalyst life, and is ready for commercialization.
Bench scale and lab scale systems are important early-stage tools for assessing and scaling new technology.
Application are a precursor to larger pilot and demonstration scale plants.
Researchers can then plot reaction yield and selectivity under a variety of operating conditions( Temp. Pressure Change solvent and volume.) Reactor volumes in bench and lab scale systems are typically less than 1000ml.
The most common operating configurations at the bench or lab scale are batch for continuous stirred tank reactor (CSTR), or autoclave etc.
Pilot plants Scale provide the first window into continuous processing and often incorporate unreacted feed or product recycle. They are the workhorse of the process development world. Catalyst performance tests are carried out to determine, or confirm, yield and selectivity data, and the lifetime of the catalyst is measured under a variety of operating conditions. Reactor size at the pilot plant scale typically ranges from 1 and 100 litres.
Demonstration Scale differ from pilot plants in that the equipment and process flowsheet much more closely resemble commercial scale operations.
Extended operating runs permit catalyst lifetime studies over a longer period of time, while significant quantities of final product can be generated for market testing.
Developers need to go to through the demonstration scale to prove to the market and investors that their technology meets its performance expectations, such as product yield and properties, and catalyst life, and is ready for commercialization.
Pharmaceutical Process Scale-Up deals with a subject both fascinating and vitally important for the pharmaceutical industry—the procedures of transferring
the results of R&D obtained on laboratory scale to the pilot plant and finally to roduction scale. The primary objective of the text is to provide insight into the
practical aspects of process scale-up.
In mixing applications, scale-up is indeed concerned with increasing the linear dimensions from the laboratory to the plant size. On the other hand, processes
exist (e.g., tableting) for which “scale-up” simply means enlarging the output by increasing the speed. To complete the picture, one should point out
special procedures (especially in biotechnology) in which an increase of the scale is counterproductive and “scale-down” is required to improve the quality
of the product.
Pharmaceutical Process Scale-Up deals with a subject both fascinating and vitally important for the pharmaceutical industry—the procedures of transferring
the results of R&D obtained on laboratory scale to the pilot plant and finally to roduction scale. The primary objective of the text is to provide insight into the
practical aspects of process scale-up.
In mixing applications, scale-up is indeed concerned with increasing the linear dimensions from the laboratory to the plant size. On the other hand, processes
exist (e.g., tableting) for which “scale-up” simply means enlarging the output by increasing the speed. To complete the picture, one should point out
special procedures (especially in biotechnology) in which an increase of the scale is counterproductive and “scale-down” is required to improve the quality
of the product.
Pharmaceutical Process Scale-Up deals with a subject both fascinating and vitally important for the pharmaceutical industry—the procedures of transferring
the results of R&D obtained on laboratory scale to the pilot plant and finally to roduction scale. The primary objective of the text is to provide insight into the
practical aspects of process scale-up.
In mixing applications, scale-up is indeed concerned with increasing the linear dimensions from the laboratory to the plant size. On the other hand, processes
exist (e.g., tableting) for which “scale-up” simply means enlarging the output by increasing the speed. To complete the picture, one should point out
special procedures (especially in biotechnology) in which an increase of the scale is counterproductive and “scale-down” is required to improve the quality
of the product.
Pharmaceutical Process Scale-Up deals with a subject both fascinating and vitally important for the pharmaceutical industry—the procedures of transferring
the results of R&D obtained on laboratory scale to the pilot plant and finally to roduction scale. The primary objective of the text is to provide insight into the
practical aspects of process scale-up.
In mixing applications, scale-up is indeed concerned with increasing the linear dimensions from the laboratory to the plant size. On the other hand, processes
exist (e.g., tableting) for which “scale-up” simply means enlarging the output by increasing the speed. To complete the picture, one should point out
special procedures (especially in biotechnology) in which an increase of the scale is counterproductive and “scale-down” is required to improve the quality
of the product.
Pharmaceutical Process Scale-Up deals with a subject both fascinating and vitally important for the pharmaceutical industry—the procedures of transferring
the results of R&D obtained on laboratory scale to the pilot plant and finally to roduction scale. The primary objective of the text is to provide insight into the
practical aspects of process scale-up.
In mixing applications, scale-up is indeed concerned with increasing the linear dimensions from the laboratory to the plant size. On the other hand, processes
exist (e.g., tableting) for which “scale-up” simply means enlarging the output by increasing the speed. To complete the picture, one should point out
special procedures (especially in biotechnology) in which an increase of the scale is counterproductive and “scale-down” is required to improve the quality
of the product.
The collection and evaluation of data, from the process design stage through commercial production, which establishes scientific evidence that a process is capable of consistently delivering quality products. (FDA)
Documented evidence which provides a high degree of assurance that a specific process will consistently result in a product that meets predetermined specifications and quality characteristics. (WHO)
The documented evidence that the process, operated within established parameters, can perform effectively and reproducibly to produce a medicinal product meeting its predetermined specifications and quality attributes.(EMA)
The collection and evaluation of data, from the process design stage through commercial production, which establishes scientific evidence that a process is capable of consistently delivering quality products. (FDA)
Documented evidence which provides a high degree of assurance that a specific process will consistently result in a product that meets predetermined specifications and quality characteristics. (WHO)
The documented evidence that the process, operated within established parameters, can perform effectively and reproducibly to produce a medicinal product meeting its predetermined specifications and quality attributes.(EMA)
Design Qualification( DQ) is a verification process on the design to meet particular requirement relating to the quality of Pharmaceutical and manufacturing process.
DQ plan covers user requirement, user specification, Technical specification and DQ report.
Operational Qualification (OQ) is the process of testing to ensure that the individual and combined systems function to meet agreed performance criteria and to check how the result of testing is recorded. The purpose is to ensure that all the dynamic attributes comply with the original design.
Performance qualification (PQ), also called process qualification, is the process of testing to ensure that the individual and combined systems function to meet agreed performance criteria on a consistent basis and to check how the result of testing is recorded. The purpose is to ensure that the criteria specified can be achieved on a reliable basis over a period of time.
Process Validation :- Owners are responsible for Validating Their Processes (personnel, equipment, methods, SOPs) to ensure compliance to cGMP/GLP regulations.
Solvent system modified to isopropanol / ethyl acetate containing hydrogen bromide from methanol / ethyl acetate to reduce formation of third impurity. Original process used chloroform.
Concentration was increased threefold increasing throughput and reducing solvent waste.
Labetalol Process –Step 2, Process Development
Large excess of dibenzylamine used to ensure reaction driven to completion (cheap reagent and easily washed out)
Propylene oxide added as it reacts with HBr side-product as it’s produced. Presence of HBr would neutralise dibenzylamine and no reaction to give product would occur. Propylene bromohydrin side-product easily washed out.
Use gentle reflux to ensure propylene oxide doesn’t escape